References
- Johnson PW, Radford JA, Cullen MH, . Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005;23:9208–9218.
- Moskowitz CH, Nimer SD, Zelenetz AD, . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
- Schmitz N, Pfistner B, Sextro M, . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
- Yuen AR, Rosenberg SA, Hoppe RT, . Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814–822.
- Sureda A, Robinson S, Canals C, . Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455–462.
- Anderlini P, Saliba R, Acholonu S, . Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257–264.
- Chen R, Palmer JM, Popplewell L, . Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803–808.
- Falini B, Pileri S, Pizzolo G, . CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1–14.
- Re D, Thomas RK, Behringer K, . From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553–4560.
- Chen R, Gopal AK, Smith SE, . Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 283.
- Chen RW, Gopal AK, Smith SE, . Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011;29(Suppl.): Abstract 8031.
- Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res 1999;5:3920–3927.
- Gan PP, McCarroll JA, Po'uha ST, . Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 2010;9:1339–1348.
- Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194–204.